Document:

Supply Agreement between Lawrence Laboratories and Cadence Pharmaceuticals, Inc

 Exhibit 10.1 
 CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 
  
  

SUPPLY AGREEMENT 
 between 
 LAWRENCE LABORATORIES 

and 

CADENCE PHARMACEUTICALS, INC. 
 effective as of December 1, 2010 
  

 

  
 i 

 TABLE OF CONTENTS 

 

					
	 Article
	  	 	  	Page
	1	  	Definitions	  	2
	2	  	Supply of Products	  	6
	3	  	Terms and Conditions of Purchase and Sale	  	9
	4	  	Regulatory Matters	  	17
	5	  	Confidentiality	  	18
	6	  	Regulatory Matters	  	18
	7	  	Dispute Resolution	  	20
	8	  	Term; Termination	  	22
	9	  	Miscellaneous	  	23

 EXHIBITS 

 

			
	Exhibit A:	  	Specifications
	Exhibit B:	  	Initial Forecast

 SUPPLY AGREEMENT 

This Supply Agreement (the “Agreement”) is entered into and is effective as of December 1, 2010 (the
“Effective Date”) by and among Lawrence Laboratories, an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company (“BMS”) and a corporation organized under the laws of Ireland with its registered office at
Unit 12, Distribution Centre, Shannon Industrial Estate, Shannon, County Clare, Ireland (“LL”), and Cadence Pharmaceuticals, Inc., a Delaware corporation having an address at 12481 High Bluff Drive, Suite 200, San Diego,
California 92130 (“Cadence”). LL and Cadence are sometimes collectively referred to herein collectively as the “Parties” and each individually as a “Party.“ 

RECITALS 

WHEREAS, Cadence holds certain license rights in intellectual property relating to the Product (as defined below) in the United States
and Canada pursuant to that certain IV APAP Agreement dated February, 2006, between BMS and Cadence (the “IV APAP Agreement”), which sublicenses to Cadence certain intellectual property rights with respect to the United
States and Canada under that certain License Agreement dated December 23, 2002 between SCR Pharmatop, a civil law partnership organized under the laws of France, having its head office’s address at 10, Square St. Florentin, 78150
Le Chesnay, France, recorded with the Register of Commerce and Companies of Versailles under No. 407552702, and BMS (the “Pharmatop License Agreement”) and licenses to Cadence certain rights to use patents and know-how of
BMS in the same jurisdictions; 
 WHEREAS, LL has made arrangements for one of its Affiliates (as defined below) located in
Italy to manufacture the Product for supply to Cadence pursuant to this Agreement; 
 WHEREAS, LL or its Affiliate holds certain
license rights in intellectual property relating to the Product (as defined below) in Italy entitling LL or its Affiliate to use such intellectual property to manufacture the Product in Italy for supply to Cadence pursuant to this Agreement;

 WHEREAS, LL or its Affiliates have expertise in manufacturing the Product; and 

WHEREAS, Cadence desires to purchase, and LL desires to supply from its Affiliate’s facility in Italy (or such other facility as LL
may determine in accordance with this Agreement), Cadence’s requirements for the Product for use in the Territory (as defined below). 

  
 1 

 AGREEMENT 
 THEREFORE, the Parties, intending to be legally bound, agree as follows: 
 ARTICLE
1 
 DEFINITIONS 
 1.1 Defined Terms. As used in this Agreement, the following terms shall have the following meanings: 
 “Affiliate” of a Party means any corporation, firm, partnership or other entity that directly or indirectly Controls, is Controlled by or is under common Control with such Party.

 “Agreement” has the meaning set forth in the Introductory Paragraph. 

“Applicable Law” means any applicable federal, state, local or foreign statute, law, ordinance, rule or
regulation, judicial order or industry standard imposed by regulation or law, including without limitation the laws of, and regulations promulgated under, the FDCA or the Canadian equivalent of the FDCA. 

“BMS” has the meaning set forth in the Introductory Paragraph. 

“Business Day” means any day other than a Saturday, a Sunday or a United States Federal, EU, Irish or
Italian holiday. 
 “Cadence” has the meaning set forth in the Introductory Paragraph.

 “Cadence Party” has the meaning set forth in Section 6.1. 

“cGMP” means all current good manufacturing practices under 21 C.F.R. 210, as amended from time to time,
or any successor regulation. 
 “Claim” means any claim (including without limitation, product
liability claims, strict liability or tort claims and intellectual property infringement claims), action, suit, governmental investigation or other proceedings made or brought by or on behalf of a Third Party against any Cadence Party or any LL
Party, as the case may be, including without limitation enforcement actions by the FDA or other applicable Drug Regulatory Authorities and claims for infringement of intellectual property and for bodily injury, death or property damage. 

“Confidential Information” has the meaning set forth in the IV APAP Agreement. 

  
 2 

 “Contract Year” will mean the twelve-month period beginning
on the first day of the month following the date on which the Facility NDA is approved by FDA, and each successive twelve-month period thereafter for the duration of this Agreement. 

“Control” means (a) with respect to Technology or technical information, the possession by a Party
of the ability to grant a license or sublicense of such Technology or technical information as provided herein without violating the terms of, or requiring a consent under, any agreement or arrangement between such Party and any Third Party and
(b) when used with respect to any Person means the power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract, or otherwise. “Controlled”
and “Controlling” shall have correlative meanings. 
 “Demand” has the meaning
set forth in Section 7.2. 
 “Dispute” has the meaning set forth in Section 7.1.

 “Dollar” or “$” means United States dollars, the lawful currency of the
United States. 
 “Drug Regulatory Authority” means any governmental authority or
instrumentality with responsibility for granting any licenses, approvals, authorizations (e.g., the NDA) or granting pricing and/or reimbursement approvals necessary for the marketing and sale of pharmaceutical products in any regulatory
jurisdiction. 
 “Effective Date” has the meaning set forth in the Introductory Paragraph.

 “EMA” means the European Medicines Agency, or any successor agency. 

“Facility” has the meaning set forth in Section 3.9. 

“Facility NDA” means an NDA filed with the FDA by Cadence with respect to Product to be manufactured
under this Agreement. 
 “FDA” means the United States Food and Drug Administration or any
successor agency. 
 “FDCA” means the Federal Food, Drug & Cosmetics Act, 21 U.S.C. 321
et seq., any amendments or supplements thereto, or any regulations promulgated or adopted thereunder. 

“Firm Order” has the meaning set forth in Section 3.2(a). 

“Force Majeure” means any circumstances that are not within the reasonable control of the Person affected
thereby, including without limitation an act of God, terrorist attack, war, insurrection, riot, strike or labor dispute, shortage of materials, fire, explosion, flood, government requisition or allocation, breakdown of or damage to plant, equipment
or facilities (to the extent that, in the event of a breakdown only, such plant, 

  
 3 

 
equipment or facilities were reasonably maintained), mandated requisition or allocation, interruption or delay in transportation, fuel supplies or electrical power, embargo, boycott, order or act
of civil or military authority. 
 “Forecast” has the meaning set forth in Section 3.1.

 “Incoterms” means the year 2000 edition of the official International Chamber of
Commerce’s rules for the interpretation of trade terms or any successor set of rules, guidelines or terms developed thereunder. 
 “Indemnified Party” has the meaning set forth in Section 6.3. 
 “Indemnifying Party” has the meaning set forth in Section 6.3. 
 “Initial Forecast” has the meaning set forth in Section 3.1. 
 “IV APAP Agreement” has the meaning set forth in the Recitals. 
 “LL” has the meaning set forth in the Introductory Paragraph. 
 “LL Party” has the meaning set forth in Section 6.2. 
 “Losses” means, collectively, any and all liabilities, damages, reduction in value, costs, expenses, including reasonable fees and disbursements of counsel and any consultants or experts
and expenses of investigation, obligations, liens, assessments, court costs, arbitration or mediation fees, judgments, fines and penalties imposed upon or incurred by an Indemnified Party (including, until such time as the Indemnifying Party assumes
control of a given Claim, reasonable attorneys’ fees and costs of litigation pertaining to such Claim). 

“Materials” has the meaning set forth in Section 2.5(a). 

“Minimum Purchase Requirement” has the meaning set forth in Section 2.3. 

“NDA” means a new drug application or an abbreviated new drug application, including any amendments or
supplements thereto, filed by Cadence with the FDA pursuant to the FDCA, or any comparable filing with any Drug Regulatory Authority in Canada, and includes any Common Technical Document for the Registration of Pharmaceuticals for Human Use filed
with the FDA or any other Drug Regulatory Authority in the Territory. 
 “Parties” has the
meaning set forth in the Introductory Paragraph. 
 “Party” has the meaning set forth in the
Introductory Paragraph. 
 “Person” means any individual, firm, corporation, partnership,
limited liability company, trust, joint venture, governmental authority or other entity. 

  
 4 

 “Pharmatop License Agreement” has the meaning set forth in
the Recitals. 
 “Price Adjustment Method” has the meaning set forth in Section 2.2(d).

 “Product” means the sterile, non-pyrogenic formulation of paracetamol (acetaminophen)
intended for intravenous infusion with a concentration of 10 mg/ml in 100 ml vials as more particularly set forth in the Specifications. Product shall be packaged with 12 vials per shrink-wrapped pack. Product will be available in 12 vials per case
(single pack) or 24 vial per case (two packs). 
 “Quality Agreement” has the meaning set forth
in Section 3.8. 
 “Reconciliation Payment” has the meaning set forth in
Section 2.3(b). 
 “Reconciliation Price” has the meaning set forth in Section 2.3(b).

 “Regulatory Approval” means with respect to the Product in any regulatory jurisdiction in the
Territory, approval from the applicable Drug Regulatory Authority sufficient to market and sell the Product in such jurisdiction. 
 “Specifications” means the specifications set forth on Exhibit A, as amended by the Parties pursuant to the terms of the Quality Agreement. 

“Supply Price” has the meaning set forth in Section 2.2. 

“Supply Term” means the period beginning on the first day of the first Contract Year and terminating
thirty six (36) consecutive months later, unless extended by the mutual agreement of the Parties. 

“Technology” means and includes all inventions, discoveries, improvements, trade secrets, know-how,
processes, procedures, research records, records of inventions, test information, formulae, drawings, specifications, instructions, techniques, data, market surveys and other similar proprietary methods, materials or property, whether or not
patentable, relating to the Product, including but not limited to (a) samples of, methods of production or use of, and structural and functional information pertaining to, chemical compounds, proteins or other biological substances,
(b) data, formulations, techniques and know-how, and (c) rights under patents, patent applications, and copyrights. 
 “Territory” means the United States (including Puerto Rico and all U.S. possessions and territories) and Canada. 

“Third Party” means a Person who or which is neither a Party nor an Affiliate of a Party. 

  
 5 

 ARTICLE 2 
 SUPPLY OF PRODUCTS 
 2.1 Supply and Purchase. 

(a) During the Supply Term and upon the terms and conditions set forth in this Agreement, LL shall, or shall cause its Affiliates to,
manufacture, or cause the manufacture of, and supply to Cadence certain quantities of the Product ordered pursuant to Firm Orders hereunder, subject to variations permitted by Section 3.2(a). Cadence shall purchase from LL and its Affiliates
all of the Product ordered by Cadence pursuant to Firm Orders hereunder. LL shall have no obligation to accept any Firm Order that calls for the delivery of the Product following the end of the Supply Term. 

(b) The Product shall be in finished vials, labeled and packed, at Cadence’s option, in cases of 12 or 24 vials per case.

 2.2 Supply Price 
 The “Supply Price” for the Product shall be as follows: 
 (a)
First Contract Year:  
  

					
	 Number of vials
ordered during First
Contract
Year*
	  	 First Contract Year
Supply Price for

Per 12-pack**
	  	 First Contract Year
Supply Price for

Per 24-pack**

	 [***]
	  	$[***]	  	$[***]
	 [***]
	  	$[***]	  	$[***]
	 [***]
	  	$[***]	  	$[***]

  

	*	Pricing may not be applied retroactively. (E.g., [***]) Price breaks effective on full lot purchases subsequent to meeting volume requirement.

  

	 	(i)	If the First Contract Year commences on or after [***], a pricing adjustment in accordance with the Price Adjustment Method may be applied; provided, however,
that if the First Contract Year commences on or after [***] as a result of [***], the Price Adjustment Method may not be applied. 

 (b) Second Contract Year:  
  

					
	 No. of vials ordered
	  	 Supply Price

Per 12-pack
	  	 Supply Price

Per 24-pack

	 [***]
	  	$[***]	  	$[***]

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 6 

  

	 	(ii)	If the Second Contract Year commences on or after [***], a pricing adjustment in accordance with the Price Adjustment Method may be applied; provided, however,
that if the Second Contract Year commences on or after [***] as a result of [***], the Price Adjustment Method may not be applied. 

 (c) Third Contract Year: 
  

					
	 No. of vials ordered
	  	 Supply Price

Per 12-pack
	  	 Supply Price

Per 24-pack

	 [***]
	  	$[***]	  	$[***]

  

	 	(i)	A pricing adjustment in accordance with the Price Adjustment Method may be applied upon first day of the Third Contract Year. 

(d) Price Adjustment Method: The “Price Adjustment Method” is reflected in the following formula:

 The Supply Price may be increased or decreased based upon [***]. 

All costs used to calculate changes to the Supply Price shall be converted into United States dollars using the applicable rate of
exchange quoted by Reuters Ltd. prevailing at 3:00 p.m. (GMT) on the last Business Day of the applicable Contract Year. 
 LL shall provide documentation reasonably satisfactory to Cadence to support each such Supply Price increase or decrease including, without limitation, copies of supplier’s invoices. 

(e) Payment: The Supply Price and payments shall be in U.S. Dollars. 

2.3 Minimum Purchase Requirements. 
 (a) Subject to Sections 8.2(a) and 8.2(b) of this Agreement, Cadence shall purchase the following quantities of the Product during the periods referenced below (the “Minimum Purchase
Requirement”): 
  

	 	•	 	 First Contract Year = [***] vials of Product; and 

  

	 	•	 	 Second and Third Contract Years = [***] vials of Product. 

 (b) In the event that the total number of Product vials ordered by Cadence from LL (based on Firm Orders placed) in a given Contract Year is less than the Minimum Purchase Requirement for that Contract
Year, Cadence shall pay LL a reconciliation payment 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 7 

 
within [***] from the date of receipt of LL’s valid invoice for such payment, calculated according to the formula set forth below (the “Reconciliation Payment”): 

The amount of the Reconciliation Payment shall be equal to: 
 [***]: 
 The “Reconciliation Price” for a given Contract Year
shall be equal to: 
 [***]. 
 The Reconciliation Price shall be calculated [***]. 
 2.4 Miscellaneous
Fees. Cadence shall pay LL for all additional services requested by Cadence in support of the development and submission of the Facility NDA and subsequent commitments to FDA at a rate of $[***]. Cadence shall also pay LL for any new validation
batches that may be required at a price not to exceed $[***] per batch. In each case, LL shall provide Cadence with a written estimate of all such miscellaneous fees at least [***] in advance of the commencement of work (or as mutually agreed), and
the Parties agree to work together to expeditiously resolve any disagreements as to the scope or costs of such services. No such services shall be commenced until LL receives Cadence’s valid purchase order covering such services. In the event
that the Parties are unable to reach agreement, the matter will be referred for resolution in accordance with Section 7.1 of this Agreement. LL shall invoice Cadence for the foregoing fees in accordance with the principles set forth in
Section 3.5. 
 2.5 Additional Supply Provisions 

(a) Materials. LL shall procure all materials required to produce the Product, including without limitation the active
pharmaceutical ingredient (acetaminophen) (collectively, the “Materials”) at such times, and in such amounts as required for LL to timely fulfill the Firm Orders. Both Parties agree to work together to reduce lead time for orders
and deliveries of the Materials. LL shall obtain the Materials only from suppliers listed in the NDA for the Product, and shall perform all testing of Materials required by the NDA or Quality Agreement. 

(b) Label Copy. All label copy and changes thereto on the Product label shall be the responsibility of Cadence, and LL shall affix
to the Product labels in the form most recently approved by Cadence. 
 (c) Stability Studies. LL shall perform, on an
on-going basis, all stability studies required by the Specifications, Applicable Laws, the NDA for the Product, and the Quality Agreement, at no additional cost to Cadence. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 8 

 (d) Reference Standards. Unless available through the United States Pharmacopeia,
Cadence shall provide, without charge to LL, analytical reference standards for the Product in quantities reasonably required by LL to perform its obligations under this Agreement. 

(e) Cadence Access to Facility. LL shall use its commercially reasonable efforts to provide Cadence’s employee or contractor
with reasonable access to the Facility at mutually agreeable times in order to facilitate such activities as batch record review and Product release. Any such employee or contractor of Cadence shall comply fully with the Facility’s applicable
safety, security and GMP procedures, 
 ARTICLE 3 
 TERMS AND CONDITIONS OF PURCHASE AND SALE 
 3.1 Forecasts. Within [***]
after the Effective Date, Cadence shall provide to LL Cadence’s initial forecast of its requirements for the Product that Cadence expects to order for delivery during the [***] following the Effective Date (the “Initial
Forecast”). Subsequently, prior to the first day of each calendar month during the Supply Term, Cadence shall deliver to LL an updated forecast setting forth its requirements for the Product that Cadence expects to order for delivery during
the [***] period beginning on the first day of such calendar month. Each such forecast is referred to herein as, a “Forecast” and the Parties hereto acknowledge and agree that, except for the first [***] of each such Forecast, such
Forecast shall not be binding on Cadence. 
 Notwithstanding the foregoing, in the event that the Facility NDA is not approved
by the date on which the Initial Forecast is provided to LL: 
 (a) Cadence’s requirements for the Product included therein
shall be delayed by a period of time equal to the length of time between the date on which the Initial Forecast is provided to LL and the date on which the Facility NDA is approved by the FDA; and 

(b) The first [***] of the Initial Forecast shall not be binding upon Cadence until such time as the Facility NDA is approved by the FDA.

 3.2 Ordering. 
 (a) Cadence shall submit to LL a written irrevocable firm purchase order for all Product to be purchased by it not later than [***] prior to the first requested shipping date of

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 9 

 
such Product (each, a “Firm Order”). Each such Firm Order shall include the quantity (full batches only; multiples of the minimum batch size) of the Product and the desired time
and manner of shipment and the shipping destination, and shall be limited to a single Product code (i.e., 12 vials per pack or 24 vials per pack). Any Firm Order for any Product must be for a quantity equal to the minimum batch size for such Product
as in effect from time to time or an integral multiple thereof. The minimum batch size in effect as of the date of this Agreement is [***] vials of the Product ([***] cases of 12 or [***] cases of 24). LL shall be obligated to manufacture, supply
and deliver the specified quantity of the Product in accordance with the delivery schedule set forth in each Firm Order, however, the Parties agree that the actual number of vials successfully manufactured by LL for any batch of the Product may be
within a range of plus or minus [***] percent (+/-[***]%) of the minimum batch size or of the actual number of vials ordered by Cadence pursuant to a Firm Order. The number of vials of Product supplied by LL pursuant to a Firm Order may only vary
from the amount actually ordered by Cadence within such limits, and LL may ship to Cadence, and Cadence shall purchase, such greater or lesser number of vials in full satisfaction of such Firm Order, provided that Cadence shall only be
required to purchase such number of vials actually supplied to Cadence. LL shall provide to Cadence no less than [***] prior written notice of any change in the minimum batch size. Within [***] following receipt of each Firm Order, LL shall notify
Cadence as to whether LL anticipates that it will be unable to deliver the specified quantity of Product within the timeframe set forth in the Firm Order. In the event LL fails to so notify Cadence, the quantity and time specified in each such Firm
Order shall be deemed accepted by LL. Firm Orders may be amended by mutual agreement of the Parties, with no resulting penalty or cost to Cadence. LL shall exercise commercially reasonable efforts to comply with changes to Firm Orders that Cadence
may request, but shall not be liable for its inability to do so. 
 (b) No terms and conditions contained in any purchase order,
acknowledgment, invoice, bill of lading, acceptance or other preprinted form issued by either Party shall be effective to the extent they are inconsistent with or modify the terms and conditions contained herein. 

3.3 Shipping Document. Each shipment of Product shall include a certificate of analysis and a packing slip that describes the
Product, the date of manufacture, traceable lot or batch number(s), quantities, shipment date and destination and such additional information as the Parties may agree in writing from time to time. 

3.4 Delivery, Title, and Shipping. 
 (a) Delivery of Product shall be FCA (Incoterms) Anagni, Italy, which port of departure (maritime or air) shall be specified by Cadence. LL shall arrange for shipping and insurance in the manner
customarily arranged for its own products from the point of manufacture to the port of departure and shall arrange for Italian export clearances, but Cadence shall bear the 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 10 

 
cost of such shipping and insurance, any special packing expenses and export or customs agents, all of which shall be included in LL’s invoice and paid by Cadence in accordance with
Section 3.5. Cadence shall arrange for loading, shipment, insurance from the port of departure to the ultimate destination and import customs clearances at the destination country, and Cadence shall be responsible for all loading charges,
freight, insurance, import customs clearances and other shipping expenses from such port of departure to the ultimate destination. Title to the Product and risk of loss, delay or damage in transit for Product purchased by Cadence shall pass to
Cadence when a shipment of the Product is placed at the disposal of Cadence’s carrier at the port of departure. Cadence shall cause its carrier to inspect all Product for physical damage prior to shipment, and Cadence shall promptly notify LL
of any such physical damage. Cadence shall bear the cost of all such pre-shipment inspection. LL and its Affiliates shall not have any responsibility for any loss or damage to any Product that occurs after LL or its export or customs agent places
the Product at the disposal of Cadence’s carrier, nor shall any loss or damage to any Product that occurs following such placement at the disposal of Cadence’s carrier obviate Cadence’s obligation to purchase and pay for such Product.
Without limiting LL’s right to recover the full invoiced amount for the Product and as partial security therefor, Cadence shall cause each shipment of Product to be insured for the full invoiced amount of each shipment. Cadence shall provide to
LL proof, satisfactory to LL, of such insurance. 
 The ultimate destination country of each shipment hereunder shall be in the
Territory. 
 (b) LL shall place the Product at the disposal of Cadence’s carrier at port of departure (maritime or air)
for shipment to Cadence or its designee, appropriately labeled with a traceable lot or batch number and packaged for shipping in the standard commercial packaging materials customarily used by LL not later than the shipping date requested by Cadence
in its Firm Order. If Cadence requests a first shipping date that is less than [***] after the delivery to LL of the applicable Firm Order, LL shall use reasonable commercial efforts to meet such earlier delivery date, but LL shall not be in breach
of this Agreement for failing to meet such earlier delivery date. If LL or its Affiliate is unable to place any shipment at the disposal of Cadence’s carrier by the date described in the first sentence of this paragraph, in addition to any
other remedies available to Cadence pursuant to this Agreement or otherwise, LL shall provide Cadence with updated delivery information (including estimated delivery date(s)) in writing on a weekly basis until such shipment has been made available
to Cadence’s carrier. 
 (c) Cadence shall make arrangements with a carrier to pick up each shipment of Product at the
designated port of departure (maritime or air) and to transport such shipment of Product to Cadence or its designee. Cadence shall notify LL in advance in writing of the name of the carrier and shall provide such other information as may be
necessary for LL to place the Product at the disposal of such carrier at the port of departure. Cadence shall have sole responsibility for the import of the Product into the Territory and for obtaining all import and import-related customs permits
and clearances; provided, however, that LL and its Affiliates 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 11 

 
shall promptly provide to Cadence all information and documentation reasonably requested by Cadence in order to obtain such permits and clearances. 

(d) In the event of any shortage of supply of Product due to Force Majeure, LL shall allocate its available supply of Product between it
and its Affiliates, its and its Affiliates’ other customers and Cadence on a pro rata basis based on the aggregate firm orders for the Product, which allocation shall be determined by LL in good faith. 

3.5 Invoicing and Payment. 
 (a) LL shall invoice Cadence for the Product in Dollars at the time of shipment. Each invoice shall include the invoice number, the Firm Order number, unit price and total price of the Product
contained in the shipment. 
 (b) Cadence shall pay LL within [***] after the receipt of any undisputed invoice. All payments to
be made hereunder to LL shall be made in Dollars by wire transfer of immediately available funds to such bank account as may be designated by LL in writing from time to time, unless the Parties agree to settle such payments through other means. In
the event Cadence disputes any invoice, Cadence shall pay any undisputed amount as and when due hereunder and shall pay the additional amount, if any, owed with respect to such invoice not later than [***] following the resolution of such dispute.

 (c) Any undisputed payment not made as and when due shall bear interest at the rate of [***] percent ([***]%) per annum,
compounded daily, from the due date to the date of payment. In addition to but without limiting the preceding sentence, LL shall have the right to suspend future shipments of Product to Cadence if LL does not receive payment within [***] after the
date of any invoice, other than invoices subject to a bona fide dispute. LL shall resume shipments of Product upon receiving such late payment and, if requested by LL, reasonable assurances as to payment of future invoices. 

3.6 Inspection; Non-Conforming Product. 
 (a) Cadence shall promptly inspect or cause to be inspected all shipments of Product hereunder. Within [***] after receipt by Cadence of any shipment of Product, Cadence may reject any lot or portion
thereof which, at the time LL placed the Product at the disposal of Cadence’s carrier, (i) failed to conform to the Specifications, (ii) was not manufactured in full conformance with Applicable Laws (including, without limitation,
U.S. cGMPs) or the terms of this Agreement, or (iii) for which the related batch record does not demonstrate conformance with the approved manufacturing process. Upon any such determination by Cadence, Cadence shall notify LL by sending LL
notice of the lot or batch numbers of the rejected Product, together with an indication of the specific basis for rejection and a sample of the rejected goods. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 12 

 
Notwithstanding the foregoing, if the discovery of the non-conformity of any Product could not reasonably have been discovered until after such [***] period, Cadence shall notify LL of such
non-conformity promptly following the discovery thereof. Cadence shall not be entitled to reject any shipment or any portion thereof where it can be proven that the damage to the Product occurred following the time that LL placed the Product at the
disposal of Cadence’s carrier, and Cadence’s sole remedy shall be against the carrier or under any applicable insurance. LL shall have the right to examine and test any Product that Cadence claims to be non-conforming. If it is determined
that there is any such failure to conform to Specifications at the time that LL placed the Product at the disposal of Cadence’s carrier, LL and Cadence shall cooperate to determine the cause of the non-conformity. 

(b) In the event that LL and Cadence do not resolve any issue where it is asserted that a batch of Product does not conform with the
Specifications within [***] after LL notifies Cadence that LL disagrees with Cadence’s belief as to the non-conformity of such Product at the time that LL placed the Product at the disposal of Cadence’s carrier, the Parties shall submit a
sample of the disputed Product to an independent laboratory, mutually selected by the Parties, for testing, and the results of such testing shall be binding upon the Parties, absent fraud or manifest error on the part of the independent laboratory.
The Party whose assertion as to the conformity or nonconformity of the Product in question is not supported by the results of the testing of the independent laboratory shall bear all costs and expenses of such testing. If the results of such testing
by such independent laboratory are inconclusive, then (i) all costs and expenses of such testing shall be borne by the Parties in equal shares and (ii) the Parties shall share equally the Supply Price of such Product and the freight,
insurance and other shipping expenses, fees, duties, taxes and levies incurred by the Parties in connection therewith, and Cadence shall pay to LL one-half of such Supply Price and other items within [***] after the receipt of such inconclusive
results; and (iii) LL shall promptly replace any such Product and deliver FCA, in accordance with Section 3.4, replacement conforming Product (even if such replacement entails shipping Product subsequent to the Supply Term), which shall be
purchased and paid for by Cadence in accordance with Article 2 and Section 3.5 of this Agreement. 
 (c) Cadence shall, as
requested by LL in its sole discretion: (i) return promptly to LL at LL’s expense all properly rejected Product or (ii) destroy such non-conforming Product in accordance with FDA guidelines or send such non-conforming Product to a
destruction facility of LL’s choice for destruction at LL’s expense. Cadence shall not be required to pay LL for any Product that has been properly rejected, and LL shall reimburse or credit Cadence for the freight, insurance and other
shipping expenses, fees, duties, taxes and levies for any shipment of Product that is properly rejected. LL shall promptly replace any properly rejected Product and supply to Cadence conforming Product (even if such replacement entails shipping
Product subsequent to the Supply Term). Cadence shall pay the 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 13 

 
Supply Price and all shipping costs (which shall include the cost of returning the Product to LL and reshipping such Product to Cadence or its designee) for any Product improperly rejected.

 3.7 Obsolescence Charge. To the extent that LL purchases inventories of materials, components or other supplies
pursuant to Cadence’s Forecast (based on vendor lead time), and such materials, components or other supplies become unusable as a result of a change to the Specifications requested by Cadence, [***] such inventories that are unique to
Cadence’s configuration of the Product and that were purchased but unused and cannot reasonably be used by LL for any other purpose. 
 3.8 Quality Control. LL (and/or one of its Affiliates) and Cadence shall enter into a quality agreement (the “Quality Agreement”) within [***] following the execution of
this Agreement containing quality terms consistent with Applicable Law and such other terms as are mutually satisfactory to the Parties and not inconsistent with this Agreement. LL shall comply with all of the provisions and requirements of the
Quality Agreement in manufacturing, testing and supplying Product to Cadence. Any breach of the Quality Agreement shall be deemed a breach of this Agreement. In the event of any conflict between the terms of this Agreement and the Quality
Agreement with respect to quality assurance or quality control matters, the terms of the Quality Agreement shall control. 
 3.9
Change of Supplier or Facility. LL may upon [***] prior written notice to Cadence change the manufacturing facility used in the manufacturing of the Product (the “Facility”) to another facility, provided that any such change
in the manufacturing facility shall be expressly conditioned upon: (a) [***]; (b) [***]; (d) [***]; and (e) [***]. 
 3.10 Recalls. Each Party shall notify the other by telephone within [***] hours after receiving any information, request or directive giving rise to a good faith belief that a recall of any Product
manufactured pursuant to this Agreement is or may be required under Applicable Law or is or may be otherwise necessary to avoid risk of injury or liability. Notwithstanding anything in this Agreement or the Quality Agreement to the contrary, Cadence
shall have sole discretion over whether and under what circumstances to require the recall of the Product in the Territory, unless a Drug Regulatory Authority in the Territory issues or requests a recall or takes similar action in connection with
such Product. 
 In the event that LL, in good faith, believes that a recall is required under Applicable Law or is otherwise
necessary to avoid risk of injury, it shall inform Cadence by providing written notice thereof to Cadence specifying, in reasonable detail, the nature and all relevant circumstances giving rise to LL’s belief that a recall is warranted, and
information regarding the affected Product. Within [***] following Cadence’s receipt of such written notification (or sooner if exigent circumstances exist or otherwise are required in order to comply with Applicable Law), the Parties shall
discuss the circumstances giving rise to such notification and 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 14 

 
the content of such notification, and, if so required, the timing and breadth of the recall, the strategies and notifications to be used by Cadence to effect the recall, and other related issues.
In the event that LL recommends to Cadence, in good faith, that a recall of a particular batch or batches of the Product should be conducted, and Cadence declines to recall such Product, LL shall be entitled to indemnification pursuant to
Section 6.2 of this Agreement. 
 LL and Cadence each shall maintain such traceability records as are sufficient and as may
be necessary to permit a recall, product withdrawal or field correction of any Product. Each Party shall provide full cooperation and assistance to the other Party in connection with any recall as may be reasonably requested by the other Party.

 (a) If a Product recall results from: (i) the failure of any Product, packaging or labeling supplied hereunder to
conform to the Specifications; (ii) the failure of any Product, packaging or labeling supplied hereunder to comply with Applicable Laws or the terms of this Agreement, including the Quality Agreement, at the time the Product was delivered by LL
to Cadence’s carrier; (iii) any negligent, grossly negligent or willful act or omission by LL or its Affiliates, including without limitation the negligent or grossly negligent manufacture of the Product, LL shall: (x) credit to
Cadence an amount equal to the total purchase price paid by Cadence to LL for the Product so recalled, plus Cadence’s actual cost for direct material and direct labor furnished by Cadence or its contracting parties in connection with the
manufacture of the recalled Product, (y) reimburse Cadence for all expenses associated with the conduct of the recall action (e.g. advertising, mailing, administration, travel, etc.), and (z) indemnify and hold Cadence harmless from and
against any and all damages, costs or charges, lawsuits or expenses associated with or resulting from any such recall, including reasonable legal fees and disbursements. 
 (b) If a Product recall results from: (i) improper handling, shipping or storage of the Product after delivery by LL to Cadence’s designated carrier, (ii) the inadequate or misleading
nature of any text appearing on the packaging or labeling of the Product in compliance with the Specifications; (iii) any negligent, grossly negligent or willful act or omission by Cadence, or (iv) due to circumstances other than those
described in Section 3.10(a), above, then LL shall have no liability with respect to the recall and Cadence shall indemnify, defend and hold LL and each other LL Indemnitee from any and all Losses suffered by such LL Indemnitee arising or
related to such recall. 
 The rights and remedies available to each Party under this Section 3.10 are not exclusive and
shall be in addition to all other right and remedies available to such Party at law and in equity. 
 3.11 Product
Complaints. Each Party shall notify the other Parties regarding Product complaints as agreed between the Parties in the Quality Agreement. 
 3.12 Representations, Warranties and Covenants. 
 (a) LL represents,
warrants and covenants that the Product when delivered FCA at the designated port of departure Incoterms in accordance with Section 3.4 shall (i) conform to the Specifications; (ii) be manufactured, packaged, tested, stored, handled
by it and 

  
 15 

 
its Affiliates in compliance with the Specifications, this Agreement, the Quality Agreement and all Applicable Laws; (iii) be shipped to Cadence within [***] after the date of manufacture;
and (iv) at the time of that LL places the Product at the disposal of Cadence’s carrier, not be adulterated or misbranded within the meaning of the FDCA. Notwithstanding the foregoing, LL does not represent, warrant or covenant against any
Product becoming adulterated or misbranded within the meaning of the FDCA or ceasing to conform to the Specifications as a result of an act or omission or damage caused by Cadence or any Third Party (including any carrier of Cadence) after placement
of the Product at the disposal of Cadence’s carrier pursuant to Section 3.4. LL represents, warrants and covenants that LL or its Affiliate shall transfer to Cadence good and marketable title to the Product free from any and all liens,
mortgages or encumbrances of any kind created by LL and its Affiliates and its and their suppliers and creditors. 
 (b) LL
represents, warrants and covenants that it and its Affiliates hold and will continue to hold during the Supply Term sufficient rights in all manufacturing processes and Technology necessary for the manufacture and supply of the Product. 

(c) LL represents, warrants and covenants that as of the date hereof it has not received written notice of any pending or threatened
Claim that would interfere with LL’s performance under this Agreement or that materially and adversely affects the rights and interests of Cadence hereunder. 
 (d) LL represents and warrants that it is duly organized, validly existing and in good standing under the laws of Ireland, and that it has not been debarred and is not subject to debarment and that it
will not use in any capacity, in connection with the services to be performed under this Agreement, any person who has been debarred pursuant to Section 306 of the FDCA, or who is the subject of a conviction described in such section. LL agrees
to inform Cadence in writing immediately if it or any person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306, or if any action, suit, claim, investigation or legal or administrative
proceeding is pending or, to the best of LL’s knowledge, is threatened, relating to the debarment or conviction of LL or any person performing services hereunder. 
 (e) Each Party represents, warrants and covenants that the execution and delivery of this Agreement and the performance of its obligations hereunder: (i) has been authorized to enter into this
Agreement by all necessary corporate action on the part of it and its shareholders, (ii) does not conflict with or violate any requirement of Applicable Law or any of its charter documents and (iii) does not conflict with, violate or
breach or constitute a default or require any consent (which has not been obtained) under, any contractual obligation, license or court or administrative order by which it is bound. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 16 

 (f) EXCEPT AS EXPRESSLY PROVIDED IN THISAGREEMENT, NEITHER LL NOR ANY OF ITS AFFILIATES
MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, WRITTEN OR ORAL, STATUTORY OR OTHERWISE WITH RESPECT TO THE PRODUCTS (WHETHER USED ALONE OR IN COMBINATION WITH OTHER SUBSTANCES) OR ANY MANUFACTURING PROCESS USED TO MANUFACTURE
ANY PRODUCTS, INCLUDING WITHOUT LIMITATION (i) ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY IMPLIED WARRANTIES ARISING FROM COURSE OF PERFORMANCE, COURSE OF DEALING OR USAGE IN THE TRADE;
(iii) ANY WARRANTIES OF DESIGN OR DESCRIPTION OR ANY WARRANTY OTHERWISE CREATED BY ANY AFFIRMATION OF FACT OR PROMISE OR SAMPLE OR MODEL; (iv) AND ALL SUCH REPRESENTATIONS AND WARRANTIES WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT,
STRICT LIABILITY OR OTHERWISE, ARE HEREBY DISCLAIMED. 
 3.13 Force Majeure. No Party shall be considered to be in breach
of, nor shall any Party be liable for any failure to perform its obligations under, this Agreement (other than obligations to make payments of money) by reason of Force Majeure. A Party affected by Force Majeure shall give the other Party prompt
notice of any interruption of performance on account of Force Majeure, and of the resumption of such performance, and shall keep the other Party informed on a current basis as to the steps being taken to remove, and the anticipated time of removal
of, the circumstances resulting in such Force Majeure. The time for performance of any obligation hereunder that is affected by Force Majeure shall be extended by the actual time of delay caused by such Force Majeure, provided that the Party
affected by such Force Majeure uses commercially reasonable efforts to mitigate any such delay. Notwithstanding the foregoing, nothing in this Section 3.13 shall excuse or suspend the obligation to make any payment due under this Agreement in
the manner and at the time provided herein. 
 ARTICLE 4 
 REGULATORY MATTERS 
 4.1 Record Retention. Any books and records relating
to the receipt, manufacture, storage, handling or testing of any Product shall be maintained under this Agreement by a Party or its Affiliates in accordance with Applicable Law. 

4.2 Regulatory Matters. 
 (a) At all times during the Term, LL shall maintain the production facility, equipment and processes (including, without limitation, the process used in producing the Product and in performing LL’s
other obligations under this Agreement) in compliance with this Agreement, the Quality Agreement and all Applicable Laws (including, without limitation, cGMP, the FDA and, to the extent applicable, the EMA guidelines, employment and labor law
requirements, electrical, fire and safety at work codes and regulations and guidelines issued by any applicable Drug Regulatory Authorities in the Territory). LL shall make available for inspection, upon the request of Cadence, all documentation
relating to such compliance. 

  
 17 

 (b) LL shall permit representatives of Cadence to conduct inspections from time to time at
all Facilities utilized by LL and its Affiliates hereunder to manufacture the Product, as agreed between the Parties in the Quality Agreement. 
 (c) If either Party is notified that the Product manufactured at the Facility or the Facility will be subject to an inspection by FDA or any other Drug Regulatory Authority, such Party shall as soon as
possible notify the other Party by telephone and e-mail of its receipt of such notification. LL shall provide Cadence copies of all Drug Regulatory Authority-issued inspection observation reports (including, without limitation, Form 483s and
equivalent forms from other Drug Regulatory Authorities) and correspondence, purged only of confidential information that is unrelated to the Product. LL shall permit Cadence’s quality assurance representative to be present at the Facility
during any such inspection by FDA or any other Drug Regulatory Authority that relates to the Product or LL’s performance under this Agreement, provided, however, that Cadence shall only have access to or communicate with the inspectors during
the facility inspection as permitted under the Quality Agreement. LL will also notify Cadence as soon as possible of LL’s receipt of any other Form 483’s or warning letters or any other significant regulatory action which LL’s quality
assurance group determines could impact the regulatory status of the Product. LL and Cadence will cooperate in resolving any concerns with any Drug Regulatory Authority, and Cadence may review LL’s responses to any such reports and
communications. LL will in its reasonable discretion incorporate into such responses any comments received from Cadence. LL will also inform Cadence of any action taken by any Drug Regulatory Authority against LL or any of its officers or employees
which may be reasonably expected to adversely affect the Product or LL’s ability to supply the Product hereunder within [***]. 
 (d) LL hereby grants Cadence the right to reference any drug master file regarding the Product or similar regulatory filing in the Territory that may now exist, or that may exist at any time during the
Supply Term or any extension thereof, in any and all regulatory or other filings made by or on behalf of Cadence, its Affiliates or sublicensees. Upon the request of Cadence, LL shall provide Cadence with a letter evidencing such right of reference.

 ARTICLE 5 
 CONFIDENTIALITY 
 5.1 Confidentiality. Any Confidential Information of the
Parties exchanged hereunder shall be governed by, and shall be maintained in confidence pursuant to, the confidentiality provisions set forth in Section 5.2 and Section 5.3 of the IV APAP Agreement. 

ARTICLE 6 

INDEMNIFICATION 

6.1 By LL. LL shall indemnify, defend and hold harmless Cadence, its Affiliates and its and their employees, subcontractors,
agents, officers and directors (each, a “Cadence Party” ) from and against all Losses by a Cadence Party that result from or arise out of any Claim against 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 18 

 
a Cadence Party to the extent such Claims or Losses are alleged to be or are in fact caused by, or are alleged to or in fact arise from or are based on any breach by LL or an LL Party of this
Agreement or the Quality Agreement; provided, however, that LL shall not be obligated to indemnify a Cadence Party under this Agreement for any Losses incurred by such Cadence Party to the extent attributable to (i) any breach of
this Agreement or the Quality Agreement by Cadence or a Cadence Party or (ii) negligence, gross negligence or willful misconduct on the part of Cadence or a Cadence Party. 

6.2 By Cadence. Cadence shall indemnify, defend and hold harmless LL, its Affiliates and its and their employees, subcontractors,
agents, officers and directors (each, an “LL Party”), from and against all Losses , liabilities, damages, fees (including, until such time as Cadence assumes control of a given Claim, reasonable attorneys’ fees and costs of
litigation pertaining to such Claim), and expenses paid or payable by an LL Party to a Third Party that result from or arise out of any Claim against an LL Party to the extent such Claim or any losses, liabilities, damages or fees, cost and expenses
in connection therewith is alleged to be or is in fact caused by, or is alleged to or in fact arises from or is based on (y) any handling, storage, consumption, administration, injection, infusion, ingestion or other use or misuse of or
exposure to the Product after the placement thereof at the disposal of Cadence’s carrier at the designated port of departure, or (z) Cadence’s decision not to recall the Product per LL’s recommendation, as set forth in
Section 3.10 of this Agreement; provided, however, that Cadence shall not be obligated to indemnify a Cadence Party under this Agreement for any Losses incurred by such Cadence Party to the extent attributable to (i) any breach of
this Agreement or the Quality Agreement by LL or an LL Party or (ii) negligence, gross negligence or willful misconduct on the part of LL or an LL Party, except to the extent that the Claim or any Losses in connection therewith results from or
arises out of (A) a failure of the Product to conform to the Specifications when placed at the disposal of Cadence’s carrier in accordance with Section 3.4; (B) any breach of this Agreement or the Quality Agreement by LL or any
LL Party; (C) any negligence, gross negligence or willful misconduct on the part of LL or any LL Party; or (D) any other matter for which LL is expressly obligated to indemnify Cadence pursuant to Section 6.1. 

6.3 Conditions to Indemnification. A Party seeking indemnification under this Article 6 (the “Indemnified
Party”) shall give prompt notice of the Claim to the other Party (the “Indemnifying Party”) and, provided that the Indemnifying Party is not contesting the indemnity obligation, shall permit the Indemnifying Party to
control and assume the defense of any litigation relating to such Claim and disposition of any such Claim unless the Indemnifying Party is also a party (or likely to be named a party) to the proceeding in which such Claim is made and the Indemnified
Party gives notice to the Indemnifying Party that it may have defenses to such Claim or proceeding that are in conflict with the interests of the Indemnifying Party, in which case the Indemnifying Party shall not be so entitled to assume the defense
of the case. If the Indemnifying Party does assume the defense of any Claim or proceeding, it (i) shall act diligently and in good faith with respect to all matters relating to the settlement or disposition of any Claim as the settlement or
disposition relates to Parties being indemnified under this Article 6, (ii) shall cause such defense to be conducted by counsel reasonably acceptable to the Indemnified Party, or (iii) shall not settle or otherwise resolve any Claim
without prior notice to the Indemnified Party and the consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed) if such settlement involves anything other than the payment of money by the
Indemnifying Party. The Indemnified Party shall cooperate with the Indemnifying 

  
 19 

 
Party in its defense of any Claim for which the Indemnifying Party has assumed the defense in accordance with this Section 6.3, and shall have the right (at its own expense) to be present in
person or through counsel at all legal proceedings giving rise to the right of indemnification. 
 6.4 Limitation of
Liability. IN NO EVENT SHALL EITHER PARTY (OR ANY OF ITS AFFILIATES OR SUBCONTRACTORS) BE LIABLE TO THE OTHER PARTY FOR, NOR SHALL ANY INDEMNIFIED PARTY HAVE THE RIGHT TO RECOVER, ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL
DAMAGES (INCLUDING LOST PROFITS OR DAMAGES FOR LOST OPPORTUNITIES), WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE (WHETHER IN ANY CLAIM FOR INDEMNIFICATION PURSUANT TO THIS ARTICLE 6 OR OTHERWISE), ARISING
(x) OUT OF THE MANUFACTURE, USE OR SALE OF ANY PRODUCT SOLD HEREUNDER OR (y) OUT OF ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT OR (z) ANY REPRESENTATION OR WARRANTY CONTAINED IN OR MADE PURSUANT TO
THIS AGREEMENT, EXCEPT THAT SUCH LIMITATION SHALL NOT APPLY TO PUNITIVE OR CONSEQUENTIAL DAMAGES PAID OR PAYABLE TO A THIRD PARTY BY AN INDEMNIFIED PARTY FOR WHICH THE INDEMNIFIED PARTY IS ENTITLED TO INDEMNIFICATION HEREUNDER. 

ARTICLE 7 

DISPUTE RESOLUTION 
 7.1 Dispute Resolution. The Parties agree to attempt to resolve any dispute, difference or question arising between the Parties or any of their Affiliates or Indemnified Parties in connection with
this Agreement or the Quality Agreement, the formation, interpretation, construction thereof or the rights, duties or liabilities of any Party or any of its Affiliates (a “Dispute”) through good faith negotiations between the
Parties in accordance with this Section 7.1 The disputing party shall provide notice of the existence and circumstances surrounding the Dispute to the other Party, in accordance with Section 9.1 of this Agreement. Within [***] after the
receipt by the non-disputing Party of any such notice, the respective officers designated below or such other officers as the Parties may designate in writing from time to time, shall meet in person to attempt to resolve the Dispute. The designated
officers are as follows: 
  

			
	For LL:	  	Glenn Peace
		  	General Manager

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 20 

			
	For Cadence:	  	Scott A. Byrd,
		  	Chief Commercial Officer

 If such dispute
is not solved by the end of a [***] period commencing upon the date on which the notice was received by the non-disputing Party, the Parties shall refer the matter to binding arbitration, as set forth in Section 7.2, below. 

7.2 Arbitration. Except as otherwise provided in this Agreement, any Dispute, not resolved through good faith negotiations as set
forth in Section 7.1 shall be resolved by binding arbitration in accordance with this Section 7.2. Any Party or any such Affiliate or Indemnified Party may require resolution of any such Dispute by arbitration hereunder by sending a
written notice to the other Party demanding arbitration of the Dispute (the “Demand”). In that event, the Dispute shall be finally resolved by arbitration in accordance with the United States Arbitration Act and the Commercial
Arbitration Rules of the American Arbitration Association. The venue for the arbitration shall be New York, New York. The arbitration shall be conducted in the English language before a panel of three (3) arbitrators. Each Party shall name one
arbitrator, and the two so named shall name the third arbitrator, who shall act as chairman. If the two party arbitrators cannot agree on a third arbitrator within [***] after the Demand, then at the request of either Party the President of the
Association of the Bar of the City of New York shall appoint the third arbitrator. The arbitrators shall promptly meet, fix the time, date and place of the hearing and notify the Parties. All documents, exhibits, testimony or other information that
is not in the English language shall be translated into the English language at the expense of the Party proffering the evidence requiring translation. The decision of the arbitrators may (depending on the equities of the case) include an award of
legal fees, costs of arbitration and interest. The panel of arbitrators shall promptly transmit an executed copy of its decision to the Parties. The decision of the arbitrators shall be final, binding and conclusive upon the Parties. Judgment on the
award rendered by the arbitrators may be entered in any court having jurisdiction thereof. Each Party retains the right to seek from a court any interim or provisional relief that may be necessary to protect the rights or property of that Party as
permitted by Section 9.3 hereof pending the establishment of the arbitrators’ determination of the merits of the controversy, and any such action shall not be deemed incompatible with this Agreement to arbitrate or a waiver of the right to
arbitration. The obligations of the Parties under this Section are specifically enforceable and shall survive any termination of this Agreement. Unless the decision of the arbitrators provides otherwise, the Parties shall bear their own costs in
preparing for the arbitration and the costs of the arbitrators shall be equally divided between the Parties. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 21 

 ARTICLE 8 
 TERM; TERMINATION 
 8.1 Term; Termination. 

(a) This Agreement shall commence on the Effective Date and shall continue for the Supply Term unless earlier terminated pursuant to this
Section 8.1, or unless otherwise extended by written agreement of the Parties. 
 (b) This Agreement shall terminate upon
the occurrence of any of the following events: 
 (i) the written consent of each of LL and Cadence to terminate
this Agreement; 
 (ii) either Party’s notice of its intent to terminate this Agreement for its convenience
(without cause and without penalty) following eighteen (18) months’ prior written notice; 
 (iii) the
termination of the IV APAP Agreement; or 
 (iv) the dissolution or termination of Cadence, other than in
connection with or following an assignment of this Agreement in accordance with Section 9.7. 
 (c) Either Party may, by
written notice to the other Party, terminate this Agreement upon the occurrence of any of the following events: 

(i) upon sixty (60) days’ prior written notice in the event of a material breach of this Agreement by the other
Party, which remains uncured by such other Party by the end of such sixty (60) day period; or 
 (ii)
effective upon written notice to the other Party, if the other Party becomes insolvent or admits in writing its inability to pay its debts as they become due, files a petition for bankruptcy, makes an assignment for the benefit of its creditors or
has a receiver, trustee or other court officer appointed for its properties or assets. 
 8.2 Consequences of
Termination. Termination of this Agreement pursuant to this Article 8 shall be without prejudice to any rights which shall have accrued to the benefit of any Party prior to such termination. Such termination shall not relieve any Party from
its obligations which are expressly indicated to survive the termination of this Agreement. All of the Parties’ rights and obligations under the immediately proceeding sentence and under Sections 3.6, 3.7, 3.10, 3.11, 4.1, 4.2(c), 4.2(d)
and 8.2 and Articles 5, 6, 7 and 9 hereof shall survive such termination for the applicable period. 

  
 22 

 (a) In the event of the termination of this Agreement by Cadence for its convenience under
Section 8.1(b)(ii), or by BMS under Section 8.1(c)(i), Cadence will reimburse LL and its Affiliates for the cost of: (i) any Product ordered under any Firm Order and received by Cadence; and (ii) any inventory of Materials
purchased by LL in order to produce the Product in accordance with any forecasts and vendor lead times to the extent that (A) such Materials are specific to the Product, and (B) LL and its Affiliate that holds such inventory are unable
reasonably to utilize such inventory for other customers or for itself or any other LL Affiliate. Upon Cadence’s request, LL shall deliver any such inventory of Materials to Cadence. Additionally, Cadence’s Minimum Purchase Requirement for
the Contract Year during which the effective date of any such termination occurs (i.e., 18 months after the notice of termination under Section 8.1(b)(ii)) shall be reduced proportionally, and Cadence shall not be obligated to purchase the
Minimum Purchase Requirement for any subsequent Contract Year. 
 (b) In the event of the termination of this Agreement for any
reason other than by Cadence for its convenience under Section 8.1(b)(ii) and by BMS under Section8.1(c)(i), (i) Cadence shall not be required to reimburse LL or its Affiliates for the cost of any inventory of Materials purchased by LL in
order to produce the Product, and (ii) Cadence shall have no obligation to purchase the Minimum Purchase Requirement for the Contract Year during which the effective date of any such termination occurs, or for any subsequent Contract Year.

 ARTICLE 9 
 MISCELLANEOUS 
 9.1 Notices. All notices, consents, requests, demands and
other communications required or permitted under this Agreement: (a) shall be in writing in the English language; (b) shall be sent by messenger, a reliable express delivery service or facsimile (with a copy sent by one of the foregoing
means), charges prepaid as applicable, to the appropriate address(es) or number(s) set forth below; and (c) shall be deemed to have been given on the date of receipt by the addressee (or, if the date of receipt is not a Business Day, on the
first Business Day after the date of receipt), as evidenced by (i) a receipt executed by the addressee (or a responsible person in his or her office), the records of the Person delivering such communication or a notice to the effect that such
addressee refused to claim or accept such communication, if sent by messenger or express delivery service, or (ii) a receipt generated by the sender’s fax machine showing that such communication was sent to the appropriate number on a
specified date, if sent by facsimile. All such communications shall be sent to the following addresses or numbers, or to such other addresses or numbers as any Party may inform the others by giving five Business Days’ prior notice: 

  
 23 

  

					
	 If to Cadence:
  

Cadence Pharmaceuticals, Inc.
 12481 High Bluff
Drive, Suite 200
 San Diego, CA 92130

Attn: Chief Commercial Officer
 Fax No.:
[***]
	  	 With a copy to:
  

Cadence Pharmaceuticals, Inc.
 12481 High Bluff
Drive, Suite 200
 San Diego, CA 92130

Attn: Legal Department
 Fax No.:
[***]
	  	
			
	 If to LL:
  
 Lawrence Laboratories
 Unit 12 Distribution Centre

Shannon Industrial Estate
 County
Clare
 Ireland
 Attn: General
Manager
 Fax No.: [***]
	  	 With a copy to:
  

Bristol-Myers Squibb Company
 1 Squibb
Drive
 New Brunswick, NJ
 Attn: Senior
Counsel Technical Operations
 Fax No.: [***]
	  	
			
	 If to BMS:
  
 Bristol-Myers Squibb Company
 1 Squibb Drive

New Brunswick, NJ
 Attn: Director, Contract
Manufacturing
 Fax No.: [***]
	  	 With a copy to:
  

Bristol-Myers Squibb Company
 1 Squibb
Drive
 New Brunswick, NJ
 Attn:
Assistant General Counsel
 Fax No.: [***]
	  	

 9.2 Governing Law. This Agreement is a contract under the laws of the State of New York and
for all purposes shall be governed by, and construed and enforced in accordance with, the laws of said State, without giving effect to any conflict of law rules. 
 9.3 Equitable Relief. The Parties acknowledge and agree that each would be irreparably damaged in the event that any provision of this Agreement is not performed by the other in accordance with its
specific terms or is otherwise breached. Accordingly, it is agreed that each Party is entitled to seek an injunction or injunctions to prevent breaches of this Agreement by the other and shall have the right to seek to specifically enforce this
Agreement and the terms and provisions hereof against the other without the posting of any bond or other security, in addition to any other remedy to which such aggrieved Party may be entitled at law or in equity; provided, however,
that the powers of the arbitrators under Section 7.2 shall be limited to enforcing the obligations provided for in this Agreement as drafted. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 24 

 9.4 Headings. All titles or captions contained in this Agreement are for convenience
of reference only and shall not limit or affect in any way the meaning or interpretation of this Agreement. 
 9.5 No Third
Party Beneficiaries. This Agreement shall be binding upon, and inure solely to the benefit of, the Parties and their permitted assigns, and nothing herein, express or implied, is intended to, or shall confer upon, any other Person any legal or
equitable right, benefit or remedy of any nature whatsoever. 
 9.6 Severability. If any term or other provision of this
Agreement is held to be invalid, illegal or incapable of being enforced by any Applicable Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal
substance of the transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate
in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest
extent possible. 
 9.7 Assignment and Subcontracting. 

(a) Except as set forth below in this Section 9.7 neither this Agreement, nor any right, interest or obligation hereunder, may
be assigned, pledged or otherwise transferred by any Party, whether by operation of law or otherwise, without the prior consent of the other Party, except that either Party may assign any of its rights or delegate any of its obligations hereunder to
any of its Affiliates, provided, that (i) the assigning Party shall provide the other Party with written notice of any such assignment or delegation, (ii) the assigning Party shall unconditionally guarantee the full and timely
performance by its Affiliate of such Party’s obligations under this Agreement, which guarantee shall be a continuing guaranty and remain in full force and effect for so long as there shall remain any obligations (including, without limitation,
any indemnification obligations) or any representations or warranties of the assigning Party under this Agreement; and (iii) such Affiliate shall have first agreed in writing to be bound by the terms of this Agreement in connection with such
delegated obligations. Cadence acknowledges that LL will delegate the manufacturing of the Product to its Affiliate, Bristol-Myers Squibb S.R.L., in Italy and that delegation to such Affiliate shall not require any further notice to Cadence.

 (b) Either Party may assign or transfer all of its rights and obligations hereunder without the prior consent of the other
Party to a successor in interest by reason of merger, consolidation or sale of substantially all of the assets of the assigning Party (and so long as such assignment or transfer includes, without limitation, all Approvals, all manufacturing assets
relating to the IV APAP Agreement, and all rights and obligations under the IV APAP Agreement); provided, that such successor in interest shall have agreed prior to such assignment or transfer to be bound by the terms of this Agreement in a
writing provided to the other Party. 
 (c) LL may not subcontract any or all of its obligations under this Agreement to any
Third Party without the prior written consent of Cadence in its sole and absolute discretion. 

  
 25 

 (d) Not withstanding anything to the contrary herein, any assignment, delegation or
subcontracting by a Party of any of its rights or obligations under this Agreement shall not relieve such Party from any of its obligations hereunder. 
 (e) Any assignment or transfer in violation of the foregoing shall be null and void and wholly invalid, the assignee or transferee in any such assignment or transfer shall acquire no rights whatsoever,
and the non-assigning non-transferring Party shall not be required to recognize, such assignment or transfer. 
 (f) Subject to
the foregoing, this Agreement shall inure to the benefit of and be binding on the Parties’ successors and permitted assigns. 
 9.8 Consents. Any consent or approval to any act or matter required under this Agreement shall be in writing and shall apply only with respect to the particular act or matter to which such consent
or approval is given, and shall not relieve any Party from the obligation to obtain the consent or approval, as applicable, wherever required under this Agreement to any other act or matter. 

9.9 Entire Agreement. This Agreement contains the entire agreement of the Parties with respect to the subject matter of this
Agreement and supersedes all prior written and oral agreements, and all contemporaneous oral agreements, relating to such subject matter. Notwithstanding the foregoing, nothing in this Agreement shall be deemed to modify, amend or waive any
provision of the IV APAP Agreement. 
 9.10 Exhibits. The Exhibits attached to this Agreement are an integral part hereof
and all references to this Agreement include such Exhibits. 
 9.11 Waivers and Amendments. No modification of or
amendment to this Agreement shall be valid unless in a writing signed by all Parties referring specifically to this Agreement and stating the Parties’ intention to modify or amend the same. Any waiver of any term or condition of this Agreement
shall be in a writing signed by the Party sought to be charged with such waiver referring specifically to the term or condition to be waived, and no such waiver shall be deemed to constitute the waiver of any other breach of the same or of any other
provision hereof. 
 9.12 No Partnership or Joint Venture. This Agreement is not intended to create, and nothing
contained herein shall be construed to create, an association, joint venture, trust or partnership, or to impose a trust or partnership covenant, obligation or liability on or with regard to the other Party. Each Party shall be severally responsible
for its own covenants, obligations and liabilities as herein provided. No Party shall be under the control of, or shall be deemed to control any other Party; no Party is the legal representative, agent, joint venturer or employee of the other Party
with respect to this Agreement for any purpose whatsoever; no Party shall have the right or power to bind the other Party; and no Party has the right or authority to assume or create any obligations of any kind or to make any representation or
warranty on behalf of any other Party, whether express or implied, or to bind any other Party in any respect whatsoever. The provisions of this Agreement are intended only for the regulation of relations between the Parties. 

  
 26 

 9.13 Absence of Presumption. With regard to each and every term and condition of
this Agreement and any and all agreements and instruments subject to the terms hereof, the Parties hereto understand and agree that the same have or has been mutually negotiated, prepared and drafted, and if at any time the Parties hereto desire or
are required to interpret or construe any such term or condition or any agreement or instrument subject hereto, no consideration shall be given to the issue of which Party hereto actually prepared, drafted or requested any term or condition of this
Agreement or any agreement or instrument subject hereto. 
 9.14 Counterparts; Facsimile Execution. This Agreement may be
executed in any number of counterparts, and by each of the Parties on separate counterparts, each of which, when so executed, shall be deemed an original, but all of which shall constitute but one and the same instrument. Delivery of an executed
counterpart of this Agreement by facsimile shall be equally as effective as delivery of a manually executed counterpart of this Agreement. 
 [Remainder of page intentionally left blank.] 

  
 27 

 SIGNATURE PAGE TO SUPPLY AGREEMENT 

IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the day and year first above written. 

 

			
	LAWRENCE LABORATORIES
		
	By:	 	/s/ Glenn Peace
		
	Name:	 	Glenn Peace
		
	Title:	 	General Manager
	
	CADENCE PHARMACEUTICALS, INC.
		
	By:	 	/s/ Theodore R. Schroeder
		
	Name:	 	Theodore R. Schroeder
		
	Title:	 	President and CEO

  
 28 

 EXHIBIT A 
 SPECIFICATIONS 
  

			
	Cadence Pharmaceuticals, Inc.	 	Acetaminophen, Injection for Intravenous Use

 [***] 
 Confidential/Trade Secret/Proprietary Information of Cadence
Pharmaceuticals, Inc. 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions. 

 EXHIBIT B 
 INITIAL FORECAST 
 [***] 

  
  

	***	Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted
portions.Dapper Inc. Global Share Incentive Plan (2007)

 Exhibit 4.1(A) 
 DAPPER INC. 
 GLOBAL
SHARE INCENTIVE PLAN (2007) 
 (as amended and restated on October 4,
2010) 
 1. NAME AND PURPOSE. 

1.1 This plan, which has been adopted by the Board of Directors of the Company, Dapper Inc., as amended from time to time, shall be
known as the Dapper Inc. Global Share Incentive Plan (2007) (the “Plan”). 
 1.2 The purposes of
the Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Service Providers of the Company and its affiliates and subsidiaries, if any, and to promote the
Company’s business by providing such individuals with opportunities to receive Awards pursuant to the Plan and to strengthen the sense of common interest between such individuals and the Company’s Stockholders. 

1.3 Awards granted under the Plan to Service Providers in various jurisdictions may be subject to specific terms and conditions
for such grants may be set forth in one or more separate appendix to the Plan, as may be approved by the Board of Directors of the Company from time to time. 
 2. DEFINITIONS 
 “Administrator” shall mean
the Board of Directors or a Committee. 
 “Appendix” shall mean any appendix to the Plan adopted by the Board
of Directors containing country-specific or other special terms relating to Awards including additional terms with respect to grants of restricted stock and other equity-based Awards. 

“Award” shall mean a grant of Options, a grant of Restricted Stock Units, or allotment of Shares or other equity-based
award hereunder. All Awards shall be confirmed by an Award Agreement, and subject to the terms and conditions of such Award Agreement. 
 “Award Agreement” shall mean a written instrument setting forth the terms applicable to a particular Award. 
 “Board of Directors” shall mean the board of directors of the Company. 
 “Cause” shall have the meaning ascribed to such term or a similar term as set forth in the Participant’s employment agreement or the agreement governing the provision of services by
a non-employee Service Provider, or, in the absence of such a definition: (i) conviction (or plea of nolo contendere) of any felony or crime involving 

 
moral turpitude or affecting the Company; (ii) repeated and unreasonable refusal to carry out a reasonable and lawful directive of the Company or of Participant’s supervisor which
involves the business of the Company or its affiliates and was capable of being lawfully performed; (iii) fraud or embezzlement of funds of the Company or its affiliates; (iv) any breach by a director of his / her fiduciary duties or
duties of care towards the Company; and (v) any disclosure of confidential information of the Company or breach of any obligation not to compete with the Company or not to violate a restrictive covenant. 

“Committee” shall mean a compensation committee or other committee as may be appointed and maintained by the Board of
Directors, in its discretion, to administer the Plan, to the extent permissible under applicable law, as amended from time to time. 
 “Company” shall mean Dapper Inc., a Delaware corporation, and its successors and assigns. 
 “Consultant” means any entity or individual who (either directly or, in the case of an individual, through his or her employer) is an advisor or consultant to the Company or its
subsidiary or affiliate. 
 “Corporate Charter” shall mean the Certificate of Incorporation and By-laws of the
Company, and any subsequent amendments or replacements thereto. 
 “Disability” shall have the meaning ascribed
to such term or a similar term in the Participant’s employment agreement (where applicable), or in the absence of such a definition, the inability of the Participant, in the opinion of a qualified physician acceptable to the Company, to perform
the major duties of the Participant’s position with the Company because of the sickness or injury of the Participant for a consecutive period of 90 days. 
 “DGCL” shall mean the Delaware General Corporation Law or other applicable law. 
 “Fair Market Value” shall mean, as of any date, the value of Shares, determined as follows: 
 (i) If the Shares are listed on any established stock exchange or traded on the Nasdaq National Market or the Nasdaq Small Cap Market, the Fair Market Value of a Share of common stock of the Company shall
be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the common stock) on the last market trading day prior
to the day of determination, as reported in the Wall Street Journal or such other source as the Board deems reliable. 
 (ii) In
the absence of such markets for the Shares, the Fair Market Value shall be determined in good faith by the Board. 

“Options” shall mean options to purchase Shares awarded under the Plan. 

  
 2 

 “Participant” shall mean a recipient of an Award hereunder who executes an
Award Agreement. 
 “Restricted Stock” means an Award of Shares under this Plan that is subject to the terms
and conditions of Section 7. 
 “Restricted Stock Unit” shall mean the right to receive in the future, in
cash or Shares, the Fair Market Value of a Share granted pursuant to Section 7.7 of the Plan. 
 “Service
Provider” shall mean an employee, director, office holder or Consultant of the Company or its subsidiary or affiliate. 

“Shares” shall mean shares of common stock, par value US$0.0001 per share, of the Company. 

“Transaction” shall have the meaning set forth in Section 10.2. 

3. ADMINISTRATION OF THE PLAN. 

3.1 The Plan will be administered by the Administrator. If the Administrator is a Committee, such Committee will consist of such
number of members of the board of directors of the Company (not less than two in number), as may be determined from time to time by the Board of Directors. The Board of Directors shall appoint such members of the Committee, may from time to time
remove members from, or add members to, the Committee, and shall fill vacancies in the Committee however caused. 
 3.2
The Committee, if appointed, shall select one of its members as its Chairman and shall hold its meetings at such times and places as it shall determine. Actions at a meeting of the Committee at which a majority of its members are present or acts
approved in writing by all members of the Committee shall be the valid acts of the Committee. The Committee shall appoint a secretary, who shall keep records of its meetings and shall make such rules and regulations for the conduct of its business
and the implementation of the Plan, as it shall deem advisable, subject to the directives of the Board of Directors and in accordance with applicable law. 
 3.3 Subject to the general terms and conditions of the Plan, and in particular Section 3.4 below, the Administrator shall have full authority in its discretion, from time to time and at any
time, to determine (i) eligible Participants, (ii) the number of Options or Shares to be covered by each Award, (iii) the time or times at which the Award shall be granted, (iv) the vesting schedule and other terms and conditions
applying to Awards, (v) the form(s) of written agreements applying to Awards, and (vi) any other matter which is necessary or desirable for, or incidental to, the administration of the Plan and the granting of Awards. The Board of
Directors may, in its sole discretion, delegate some or all of the powers listed above to the Committee, to the extent permitted by the DGCL, its Corporate Charter or other applicable law, rules and regulations. 

3.4 No member of the Board of Directors or of the Committee shall be liable for any action or determination made in good faith
with respect to the Plan or any Award granted hereunder. Subject to the Company’s decision and to all approvals legally required, each member of the Board or the Committee shall be indemnified and held

  
 3 

 
harmless by the Company against any cost or expense (including counsel fees) reasonably incurred by him or her, or any liability (including any sum paid in settlement of a claim with the approval
of the Company) arising out of any act or omission to act in connection with the Plan unless arising out of such member’s own willful misconduct or bad faith, to the fullest extent permitted by applicable law. Such indemnification shall be in
addition to any rights of indemnification the member may have as a director or otherwise under the Company’s Corporate Charter, any agreement, any vote of stockholders or disinterested directors, insurance policy or otherwise. 

3.5 The interpretation and construction by the Administrator of any provision of the Plan or of any Option hereunder shall be
final and conclusive. In the event that the Board appoints a Committee, the interpretation and construction by the Committee of any provision of the Plan or of any Option hereunder shall be conclusive unless otherwise determined by the Board of
Directors. To avoid doubt, the Board of Directors may at any time exercise any powers of the Administrator, notwithstanding the fact that a Committee has been appointed. 
 3.6 The Administrator shall have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan and perform all acts, including the delegation of
its responsibilities (to the extent permitted by applicable law and applicable stock exchange rules), as it shall, from time to time, deem advisable; to construe and interpret the terms and provisions of the Plan and any Award issued under the Plan
(and any agreements relating thereto); and to otherwise supervise the administration of the Plan. The Administrator may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any agreement relating thereto in the
manner and to the extent it shall deem necessary to effectuate the purpose and intent of the Plan. Notwithstanding the foregoing, no action of the Administrator under this Section 3.6 not otherwise provided for herein or in an Award Agreement
shall reduce the rights of any Participant without the Participant’s consent. 
 3.7 Without limiting the generality
of the foregoing, the Administrator may adopt special Appendices and/or guidelines and provisions for persons who are residing in or employed in, or subject to, the taxes of, any domestic or foreign jurisdictions, to comply with applicable laws,
regulations, or accounting, listing or other rules with respect to such domestic or foreign jurisdictions. 
 4.
ELIGIBLE PARTICIPANTS. 
 4.1 No Award may be granted pursuant to the Plan to any person
serving as a member of the Committee or to any other Director of the Company at the time of the grant, unless such grant is approved in the manner prescribed for the approval of compensation of directors under the DGCL or applicable law. 

4.2 Subject to the limitation set forth in Section 4.1 above and any restriction imposed by applicable law, Awards may be
granted to any Service Provider of the Company, whether or not a director of the Company or its affiliates. The grant of an Award to a Participant hereunder shall neither entitle such Participant to receive an additional Award or participate in
other incentive plans of the Company, nor disqualify such Participant from receiving any additional Award or participating in other incentive plans of the Company. 

  
 4 

 5. RESERVED SHARES. 

5.1 Basic Limitation. Not more than 5,378,810 Shares may be issued under the Plan (subject to Subsection 12 below and
Section 10.1). The number of Shares that are subject to Awards outstanding at any time under the Plan shall not exceed the number of Shares that then remain available for issuance under the Plan. The Company, during the term of the Plan, shall
at all times reserve and keep available sufficient Shares to satisfy the requirements of the Plan. Shares offered under the Plan may be authorized but unissued Shares or treasury Shares. 

5.2 Additional Shares. In the event that Shares previously issued under the Plan are reacquired by the Company, such Shares shall
be added to the number of Shares then available for issuance under the Plan. In the event that an outstanding Award for any reason expires or is canceled, the Shares allocable to the unexercised portion of such Option or other Award shall be added
to the number of Shares then available for issuance under the Plan. 
 6. AWARD AGREEMENT.

 6.1 The Board of Directors in its discretion may award to Participants Awards available under the Plan. The terms
of the Award will be set forth in the Award Agreement. The date of grant of each Award shall be the date specified by the Board of Directors at the time such award is made, or in the absence of such specification, the date of approval of the award
by the Board of Directors. 
 6.2 The Award Agreement shall state, inter alia, the number of Options or Shares or
equity-based units covered thereby, the type of Option or Share-based or other grant awarded, any special terms applying to such Award (if any), including the terms of any country-specific or other applicable Appendix, as determined by the Board of
Directors. 
 7. RESTRICTED STOCK, RESTRICTED STOCK
UNITS AND OTHER EQUITY-BASED AWARDS. 
 7.1 Eligibility. Restricted Stock may be issued to all Participants either alone or in addition to other Awards granted under the Plan. The Administrator shall determine the eligible Participants
to whom, and the time or times at which, grants of Restricted Stock will be made, the number of shares to be awarded, the purchase price (if any) to be paid by the Participant (subject to Section 7.2), the time or times at which such Awards may
be subject to forfeiture (if any), the vesting schedule (if any) and rights to acceleration thereof, and all other terms and conditions of the Awards. The Administrator may condition the grant or vesting of Restricted Stock upon the attainment of
specified performance targets or such other factors as the Administrator may determine, in its sole discretion. Unless otherwise determined by the Administrator , the Participant shall not be permitted to sell or transfer shares of Restricted Stock
awarded under this Plan during a period set by the Administrator (if any) (the “Restriction Period”) commencing with the date of such Award, as set forth in the applicable Award agreement. 

  
 5 

 7.2 Terms. A Participant selected to receive Restricted Stock shall not have any
rights with respect to such Award, unless and until such Participant has delivered a fully executed copy of the Award Agreement evidencing the Award to the Company and has otherwise complied with the applicable terms and conditions of such Award.
The purchase price of Restricted Stock shall be determined by the Administrator, but shall not be less than as permitted under applicable law. Awards of Restricted Stock must be accepted within a period of 60 days (or such shorter period as the
Administrator may specify at grant) after the grant date, by executing an Award Agreement and by paying whatever price (if any) the Administrator has designated thereunder. Any right to receive or purchase Restricted Stock shall not be transferable
and shall be exercisable only by the Participant to whom such right was granted. 
 7.3 Legend. Each Participant
receiving Restricted Stock shall be issued a share certificate in respect of such shares of Restricted Stock, unless the Administrator elects to use another system, such as book entries by the transfer agent, as evidencing ownership of Restricted
Stock. Such certificate shall be registered in the name of such Participant, and shall bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award, substantially in the following form (as well as other
legend required by the Administrator pursuant to Section 18.3 below): 
 “The anticipation, alienation, attachment,
sale, transfer, assignment, pledge, encumbrance or charge of the shares represented hereby are subject to the terms and conditions (including forfeiture) of the Dapper Inc. Global Incentive Plan (2007), and an Award Agreement entered into between
the registered owner and the Company dated                     . Copies of such Plan and Award agreement are on file at Dapper Inc.”

 7.4 Custody. The Administrator may require that any share certificates evidencing such shares be held in custody by
the Company until the restrictions thereon shall have lapsed, and that, as a condition of any Restricted Stock Award, the Participant shall have delivered a duly signed share transfer deed, endorsed in blank, relating to the Shares covered by such
Award. 
 7.5 Rights as Stockholder. Except as provided in this Section and Section 7.4 above and as otherwise
determined by the Administrator and set forth in the Award Agreement, the Participant shall have, with respect to the shares of Restricted Stock, all of the rights of a holder of Shares including, without limitation, the right to receive any
dividends, the right to vote such shares and, subject to and conditioned upon the full vesting of shares of Restricted Stock, the right to tender such shares. Notwithstanding the foregoing, the payment of dividends shall be deferred until, and
conditioned upon, the expiration of the applicable Restriction Period, unless the Administrator, in its sole discretion, specifies otherwise at the time of the Award. 

  
 6 

 7.6 Lapse of Restrictions. If and when the Restriction Period expires without a prior
forfeiture of the Restricted Stock subject to such Restriction Period, the certificates for such shares shall be delivered to the Participant. All legends shall be removed from said certificates at the time of delivery to the Participant except as
otherwise required by applicable law. Notwithstanding the foregoing, actual certificates shall not be issued to the extent that book entry recordkeeping is used. 
 7.7 Restricted Stock Units. 
 (a) General. Restricted Stock Units may
be issued either alone or in addition to other Awards granted under the Plan and/or cash awards made outside of the Plan. After the Administrator determines that it will grant Restricted Stock Units under the Plan, it shall advise the Participant in
writing of the terms, conditions and restrictions related to the offer (which may include restrictions based on performance criteria, passage of time or other factors or a combination thereof) and the number of Restricted Stock Units that such
person shall be entitled to. The offer shall be accepted by execution of an Award Agreement in the form determined by the Administrator. 
 (b) Rights as a Stockholder. A Participant who is awarded Restricted Stock Units shall possess no incidents of Common Stock ownership with respect to such Restricted Stock Units unless and until
certificates representing such Shares will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant. 
 (c) Form and Timing of Payment. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s) determined by the Administrator and set forth in the Award Agreement.
The Administrator, in its sole discretion, may settle earned Restricted Stock Units in cash, Shares, or a combination of both. 

(d) Cancellation. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the
Company. 
 (e) Other Provisions. The Award Agreement shall contain such other terms, provisions and conditions not
inconsistent with the Plan as may be determined by the Administrator in its sole discretion. In addition, the provisions of Restricted Stock Units Award Agreements need not be the same with respect to each Participant who is awarded Restricted Stock
Units. 
 7.8 Other Equity-Based Awards. Other equity-based awards (including, without limitation, performance share
awards) may be granted either alone or in addition to or other Awards granted under the Plan to all eligible Participants pursuant to such terms and conditions as the Administrator may determine, including without limitation, in one or more appendix
adopted by the administrator and appended to this Plan. 

  
 7 

 8. EXERCISE OF OPTIONS. 

8.1 Options shall be exercisable pursuant to the terms under which they were awarded and subject to the terms and conditions of the
Plan and any applicable Appendix, as specified in the Award Agreement. 
 8.2 The exercise price for each Share to be
issued upon exercise of an Option shall be such price as is determined by the Board in its discretion, provided that the price per Share is not less than the par value of each Share, or to the extent required pursuant to applicable law, not less
than 100% of the Fair Market Value of a Share on the date of grant. 
 8.3 An Option, or any part thereof, shall be
exercisable by the Participant’s signing and returning to the Company at its principal office (and to the Trustee, where applicable), a “Notice of Exercise” in such form and substance as may be prescribed by the Board of Directors
from time to time, together with full payment for the Shares underlying such Option. 
 8.4 Each payment for Shares under
an Option shall be in respect of a whole number of Shares, shall be effected in cash or by check payable to the order of the Company, or such other method of payment determined by the Administrator, and shall be accompanied by a notice stating the
number of Shares being paid for thereby. 
 8.5 Until the Shares are issued (as evidenced by the appropriate entry in the
register of the Company or of a duly authorized transfer agent of the Company) a Participant shall have no right to vote or right to receive dividends or any other rights as a stockholder shall exist with respect to such Shares, notwithstanding the
exercise of the Option. The Company shall issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made for a dividend or other right the record date for which is prior to the date the Shares are
issued, except as provided in Section 10 of the Plan. 
 8.6 To the extent permitted by law, if the Shares are
traded on a national securities exchange, The Nasdaq Share Market or quoted on a national quotation system sponsored by the National Association of Securities Dealers or otherwise publicly traded or quoted, payment for the Shares underlying an
Option may be made all or in part by the delivery (on a form prescribed by the Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales proceeds to the Company in
payment of the exercise price (or the relevant portion thereof, as applicable) and any withholding taxes, or on such other terms and conditions as may be acceptable to the Administrator. No Shares shall be issued until payment has been made or
provided for, as provided herein. 

  
 8 

 9. TERMINATION OF RELATIONSHIP
AS SERVICE PROVIDER. 
 9.1 Effect of Termination; Exercise after
Termination. Unless otherwise determined by the Administrator, if a Participant ceases to be a Service Provider, such Participant may exercise any outstanding Options within such period of time as is specified in the Award Agreement or the Plan
to the extent that the Options are vested on the date of termination (but in no event later than the expiration of the term of the Option as set forth in the Option Agreement). If, on the date of termination, any Options are unvested, the Shares
covered by the unvested portion of the Option shall revert to the Plan. If, after termination, the Participant does not exercise the vested Options within the time specified in the Award Agreement or the Plan, the Option shall terminate, and the
Shares covered by such Option shall revert to the Plan. 
 In the absence of a provision specifying otherwise in the relevant
Award Agreement, then: 
 (a) in the event that the Participant ceases to be a Service Provider for any reason other than
termination for Cause or as a result of the Participant’s death or Disability, then: (i) the vested Options shall remain exercisable until the earlier of: a period of three (3) months from the Date of Termination; or expiration of the
term of the Option as set forth in Section 13; and (ii) all Restricted Stock Units still subject to restrictions, and all Restricted Stock still subject to restriction under the applicable Restriction Period, each as set forth in the Award
Agreement, shall be forfeited; 
 (b) in the event that the Participant ceases to be a Service Provider for Cause, (i) all
Options will terminate immediately upon the date of such termination for Cause, such that the unvested portion of the Options will not vest, and the vested portion of the Options will no longer be exercisable; and (ii) all Restricted Stock
Units still subject to restrictions, and all Restricted Stock still subject to restriction under the applicable Restriction Period as of the Date of Termination, each as set forth in the Award Agreement, shall be forfeited. 

(c) in the event that the Participant ceases to be a Service Provider as a result of the Participant’s Disability, the vested
Options shall remain exercisable for twelve (12) months following the Participant’s date of termination for Disability. 
 (d) in the event that the Participant dies while a Service Provider, the Option shall remain exercisable by the Participant’s estate or by a person who acquires the right to exercise the Option by
bequest or inheritance for twelve (12) months following the Participant’s date of death. 
 9.2 Date
of Termination. For purposes of the Plan and any Option or Option Agreement, and unless otherwise set forth in the relevant Award Agreement, the “Date of Termination” (whether for Cause
or otherwise) shall be the effective date of termination of the Participant’s employment or engagement as a Service Provider.  
 9.3 Leave of Absence. Unless the Administrator provides otherwise, vesting of Awards granted hereunder shall be suspended during any unpaid leave of absence. 

  
 9 

 9.4 Change of Status. A Service Provider shall not cease to be considered as such in
the case of any (a) leave of absence approved by the Company, or (b) transfers between locations of the Company or between the Company, and its parent, subsidiary, affiliate, or any successor thereof; or (c) changes in status
(employee to director, employee to consultant, etc.) provided that such change does not affect the specific terms applying to the Service Provider’s Award. 
 10. ADJUSTMENTS. 
 Upon the occurrence of any of the
following described events, a Participant’s rights to purchase Shares under the Plan shall be adjusted as hereinafter provided: 
 10.1 Changes in Capitalization. Subject to any required action by the stockholders of the Company, the number of Shares covered by each outstanding Award, and the number of Shares which have been
authorized for issuance under the Plan but as to which no Options or other Award have yet been granted or which have been returned to the Plan upon cancellation or expiration of an Option or other Award, as well as the price per Share covered by
each such outstanding Option, shall be proportionately adjusted for any increase or decrease in the number of issued Shares resulting from a share split, reverse share split, subdivision of the outstanding common stock of the Company, declaration of
a dividend payable in Shares, share dividend, combination or consolidation of the Shares into a lesser number of Shares, reclassification, or any other increase or decrease in the number of issued Shares effected without receipt of consideration by
the Company. The conversion of any convertible securities of the Company shall not be deemed to have been “effected without receipt of consideration.” Such adjustment shall be made by the Board, whose determination in that respect shall be
final, binding and conclusive. In the event of a declaration of an extraordinary dividend payable in a form other than Shares in an amount that has a material effect on the Fair Market Value of the common stock of the Company, a recapitalization, a
spin-off, or a similar occurrence, appropriate adjustments may be made in one or more of (i) the number of Shares available for future grants under Section 5, (ii) the number of Shares covered by each outstanding Award or
(iii) the exercise price under each outstanding Award; provided, however, that the Board of Directors shall in any event make such adjustments as may be required by applicable law. Except as expressly provided herein, no issuance by the Company
of shares of any class, or securities convertible into shares of any class, shall affect, and no adjustment by reason thereof shall be made with respect to, the number or price of Shares subject to an Option or other Award. 

10.2 Merger, Acquisition, or Asset Sale. (a) In the event of (i) a merger or consolidation of the Company with or into
another corporation; (ii) the consummation of a transaction that results in any other corporation, person or entity owning fifty percent (50%) or more of the outstanding voting power of the Company’s securities by virtue of the
transaction , or (iii) the sale of all or substantially all of the assets of the Company (each such event, a “Transaction”), the unexercised or restricted portion of each outstanding Award shall be assumed or an equivalent Award or
right substituted, by the successor corporation or an affiliate of the successor corporation, as shall be determined by such entity, subject to the terms hereof. Notwithstanding the foregoing, any change in the beneficial ownership of the
Company’s securities as a result of a private financing of the Company that is approved by the Board of Directors shall not be deemed to constitute 

  
 10 

 
a Transaction. As an alternative to the assumption or substitution of Awards, Awards may be cancelled in exchange for a payment to the Participant equal to the excess of (A) the Fair Market
Value of the Shares subject to the Award (whether or the Award is then exercisable (if applicable) or such Shares are then vested) as of the effective date of the Transaction over (B) the exercise price per share of the Award (if any) (a
“Cash Out”). The Cash Out payment shall be made in the form of cash, cash equivalents or securities of the surviving corporation or its parent with a Fair Market Value equal to the required amount, and such payment may be made in
installments, may be deferred until the date or dates when the Award would have become exercisable or such Shares would have vested and may be subject to vesting based on the Participant’s continuing service as a Service Provider; provided that
such vesting schedule shall not be less favorable to the Participant than the schedule under which the Award would have become exercisable or such Shares would have vested. In the event that the successor corporation or a parent or subsidiary of the
successor corporation does not provide for such an assumption, substitution or Cash Out of Awards, all Awards shall become exercisable in full on a date no later than ten (10) days prior to the date of consummation of the Transaction, provided
that unless otherwise determined by the Administrator, the exercise of all Awards that otherwise would not have been exercisable in the absence of a Transaction, shall be contingent upon the actual consummation of the Transaction. 

(b) For the purposes of this Section 10.2, an Award shall be considered assumed or substituted if, following a Transaction, the
Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the Transaction, the consideration (whether stock, cash, or other securities or property) received in the merger or sale of assets by holders of
Shares of the Company for each Share held on the effective date of the Transaction (and if holders were offered a choice of consideration, the type of consideration determined by the Administrator, at its sole discretion); provided, however, that if
the consideration received in the Transaction is not solely common stock or ordinary shares (or the equivalent) of the successor corporation or its direct or indirect parent, the Administrator may, with the consent of the successor corporation,
provide for the per share consideration to be received of the Award to be solely common stock or ordinary shares (or the equivalent) of the successor corporation or its direct or indirect parent equal in fair market value to the per share
consideration received by holders of Shares in the Transaction, as determined by the Administrator. 
 (c) In the event that the
Board of Directors determines in good faith that the exercise price of the Shares subject to an Option exceeds the Fair Market Value of such Shares, the Board of Directors may determine that such Options shall terminate effective as of the effective
date of the Transaction. 
 (d) It is the intention that the Administrator’s authority to make determinations, adjustments
and clarifications in connection with the treatment of Awards shall be interpreted as widely as possible, to allow the Administrator maximal power and flexibility to interpret and implement the provisions of the Plan in the event of Transaction,
provided that the Administrator shall determine in good faith that a Participant’s rights are not thereby adversely affected without the Participant’s express written consent. Without derogating from the generality of the foregoing, the
Administrator shall have the authority, at its sole discretion, to determine that the treatment of Awards in a Transaction may differ among individual Participants or groups of Participants. 

  
 11 

 (e) For purposes of this Section 10.2, the Fair Market Value of any security shall be
determined without regard to any vesting conditions that may apply to such security. 
 11.
NON-TRANSFERABILITY OF OPTIONS AND SHARES. 
 11.1 Except as otherwise provided by the Board of Directors in the applicable agreement evidencing the Option, no Option may be transferred other than by will or by the laws of descent and
distribution, and during the Participant’s lifetime an Option may be exercised only by such Participant. 
 11.2
Except as otherwise provided by the Board of Directors in the applicable agreement evidencing the Restricted Stock or Restricted Stock Unit, Restricted Stock and Restricted Stock Units may not be assigned, transferred, pledged or mortgaged,
other than by will or laws of descent and distribution, prior to the date on which the date on which any applicable restriction, performance or deferred period lapses. Shares for which full payment has not been made, may not be assigned,
transferred, pledged or mortgaged, other than by will or laws of descent and distribution. For avoidance of doubt, the foregoing shall not be deemed to restrict the transfer of an Participant’s rights in respect of Options or Shares purchasable
pursuant to the exercise thereof upon the death of such Participant to such Participant’s estate or other successors by operation of law or will, whose rights therein shall be governed by Section 9.1(a) hereof, and as may otherwise be
determined by the Administrator. Further restrictions on the transfer of Shares are set forth below in Section 20 below. 

12. TERM AND AMENDMENT OF THE PLAN.

 12.1 The Plan, as set forth herein, shall become effective on the date of its adoption by the Board of Directors,
subject to the approval of the Company’s stockholders. If the stockholders fail to approve the Plan within 12 months after its adoption by the Board of Directors, then any grants, exercises or sales that have already occurred under the Plan
shall be rescinded and no additional grants, exercises or sales shall thereafter be made under the Plan. The Plan shall expire on the date which is ten (10) years after the later of (i) the date of its adoption by the Board of Directors
(except as to Options outstanding on that date) or (ii) the date when the Board of Directors approved the most recent increase in the number of Shares reserved under Section 5 that was also approved by the Company’s stockholders. The
Plan may be terminated on any earlier date pursuant to Section 12.2 below. 
 12.2 Notwithstanding any other
provision of the Plan, the Board (or a duly authorized Committee thereof) may at any time, and from time to time, amend, in whole or in part, any or all of the provisions of the Plan (including any amendment deemed necessary to ensure that the
Company may comply with any regulatory requirement), or suspend or terminate it entirely, retroactively or otherwise; provided, however, that, except (x) to correct obvious drafting errors or as otherwise required by law or (y) as
specifically provided herein, the rights of a Participant with respect to Awards granted prior to such amendment, suspension or termination, may not be reduced without the 

  
 12 

 
consent of such Participant. The Administrator may amend the terms of any Award theretofore granted, prospectively or retroactively, but except (x) to correct obvious drafting errors or as
otherwise required by law or applicable accounting rules, or (y) as specifically provided herein, no such amendment or other action by the Committee shall reduce the rights of any Participant with respect to vested Awards without the
Participant’s consent. Any amendment of the Plan shall be subject to the approval of the Company’s stockholders if it (i) increases the number of Shares available for issuance under the Plan (except as provided in Section 10.1)
or (ii) materially changes the class of persons who are eligible for the grant of Awards or if such approval is required under applicable law. If the stockholders fail to approve an increase in the number of Shares reserved under Section 5
within 12 months after its adoption by the Board of Directors, then any grants, exercises or sales that have already occurred in reliance on such increase shall be rescinded and no additional grants, exercises or sales shall thereafter be made in
reliance on such increase. 
 13. TERM OF OPTION. 

Unless otherwise explicitly provided in an Award Agreement, if any Option, or any part thereof, has not been exercised and the Shares
covered thereby not paid for within ten (10) years after the date on which the Option was granted, as set forth in the Award Agreement (or any other period set forth in the instrument granting such Option pursuant to Section 6), such
Option, or such part thereof, and the right to acquire such Shares shall terminate, all interests and rights of the Participant in and to the same shall expire, and, in the event that in connection therewith any Shares are held in trust as
aforesaid, such trust shall expire. 
 14. CONTINUANCE OF ENGAGEMENT.

 Neither the Plan nor any offer of Shares or Options to a Participant shall impose any obligation on the Company or a
related company thereof, to continue the employment or engagement of any Participant as a Service Provider, and nothing in the Plan or in any Option granted pursuant thereto shall confer upon any Participant any right to continue to serve as a
Service Provider of the Company or a related company thereof or restrict the right of the Company or a related company thereof to terminate such employment or engagement at any time. 

15. GOVERNING LAW. 
 The Plan and all instruments issued thereunder or in connection therewith, shall be governed by, and interpreted in accordance with, the laws of the State off Delaware. 

16. APPLICATION OF FUNDS. 

The proceeds received by the Company from the sale of Shares pursuant to Options granted under the Plan will be used for general corporate
purposes of the Company or any related company thereof. 

  
 13 

 17. TAXES. 

17.1 Any tax consequences arising from the grant, or vesting or exercise of any Award, from the payment for Shares covered thereby,
or from any other event or act (of the Company, and/or its affiliates, or the Participant), hereunder, shall be borne solely by the Participant. The Company and/or its affiliates shall withhold taxes according to the requirements under the
applicable laws, rules, and regulations, including withholding taxes at source. Furthermore, the Participant shall agree to indemnify the Company and/or its affiliates and hold them harmless against and from any and all liability for any such tax or
interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Participant. The Company or any of its affiliates may make such provisions
and take such steps as it may deem necessary or appropriate for the withholding of all taxes required by law to be withheld with respect to Awards granted under the Plan and the exercise thereof, including, but not limited, to (i) deducting the
amount so required to be withheld from any other amount (or Shares issuable) then or thereafter to be provided to the Participant, including by deducting any such amount from a Participant’s salary or other amounts payable to the Participant,
to the maximum extent permitted under law and/or (ii) requiring the Participant to pay to the Company or any of its affiliates the amount so required to be withheld as a condition of the issuance, delivery, distribution or release of any Shares
and/or (iii) by causing the exercise and sale of any Options or Shares held by on behalf of the Participant to cover such liability, up to the amount required to satisfy minimum statutory withholding requirements. In addition, the Participant
will be required to pay any amount due in excess of the tax withheld and transferred to the tax authorities, pursuant to applicable tax laws, regulations and rules. 
 17.2 The receipt of an Award and/or the acquisition of Shares issued upon the exercise of the Options may result in tax consequences. The description of tax consequences set forth in the Plan or
any Appendix hereto does not purport to be complete, up to date or to take into account any special circumstances relating to a Participant. 
 17.3 THE PARTICIPANT IS ADVISED TO CONSULT WITH A TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES OF RECEIVING OR EXERCISING ANY AWARD IN LIGHT OF HIS OR HER PARTICULAR CIRCUMSTANCES. 

18. MARKET STAND-OFF 

If so requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with
any registration of the offering of any securities of the Company under the securities laws of any jurisdiction, the Participant shall not sell or otherwise transfer any Shares or other securities of the Company during a 180-day period or such other
period as may be requested in writing by the Managing Underwriter and agreed to in writing by the Company (the “Market Standoff Period”) following the effective date of registration statement of the Company filed under such
securities laws. The Company may require the Participant to execute a form of undertaking to this effect or impose stop transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff
Period. 

  
 14 

 19. CONDITIONS UPON ISSUANCE
OF SHARES. 
 19.1 Legal Compliance. Shares shall not be issued pursuant to the exercise
of an Option or with respect to any other Award unless the exercise of such Option or grant of such Award and the issuance and delivery of such Shares shall comply with applicable laws and shall be further subject to the approval of counsel for the
Company with respect to such compliance. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any
Shares hereunder, shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained. 

19.2 Investment Representations. As a condition to the exercise of an Option or receipt of an Award, the Board may require the
person exercising such Option or receiving such Award to represent and warrant at the time of any such exercise or the time of receipt of the Award that the Shares are being purchased only for investment and without any present intention to sell or
distribute such Shares, and make other representations as may be required under applicable securities laws if, in the opinion of counsel for the Company, such representations are required, all in form and content specified by the Board. 

19.3 Legend. The Administrator may require each person receiving Shares pursuant to an Award granted under the Plan to represent
to and agree with the Company in writing that the Participant is acquiring the shares without a view to distribution thereof and such other securities law related representations as the Administrator shall request. In addition to any legend required
by the Plan, the certificates for such shares may include any legend which the Administrator deems appropriate to reflect any applicable restrictions on transfer. All certificates for Shares delivered under the Plan shall be subject to such share
transfer orders and other restrictions as the Administrator may deem advisable under the rules, regulations and other requirements of any relevant securities authority, any stock exchange upon which the Shares are then listed or any national
securities association system upon whose system the Shares are then quoted, any applicable securities law, and any applicable corporate law, and the Administrator may cause a legend or legends to be put on any such certificates to make appropriate
reference to such restrictions. 
 20. PROXY 

The Company, at its sole discretion, may require that as a condition of grant of an Award or of exercise of an Option, the Participant be
required to grant an irrevocable proxy to any appropriate person designated by the Company, to vote all Shares obtained by the Participant pursuant to an Award at all general meetings of Company, and to sign all written resolutions, waivers,
consents etc. of the stockholders of the Company on behalf of the Participant, including the right to waive on behalf of the Participant all minimum notice requirements for meetings of stockholders of the Company. Such proxy shall remain in effect
until the consummation of an IPO, and shall be irrevocable as the rights of third parties, including investors in the Company, depend upon such proxy. The proxy shall be personal to the Participant and shall not survive the transfer of the
Participant’s Shares to a third-party transferee; provided, however, that upon a transfer of the Participant’s Shares to such a transferee (subject to the terms and conditions of the

  
 15 

 
Plan concerning any such transfer), the transferee may be required to grant an irrevocable proxy to such appropriate person as the Company, in giving its approval to the transfer, so requires.
The proxy may be contained in the Award Agreement of each Participant or otherwise as the Committee determines. If contained in the Award Agreement, no further document shall be required to implement such proxy, and the signature of the Participant
on the Award Agreement shall indicate approval of the proxy thereby granted. The holder of the proxy shall be indemnified and held harmless by the Company against any cost or expense (including counsel fees) reasonably incurred by him/her, or any
liability (including any sum paid in settlement of a claim with the approval of the Company) arising out of any act or omission to act in connection with the voting of the proxy unless arising out of his/her own fraud, bad faith or gross negligence,
to the extent permitted by applicable law. Such indemnification shall be in addition to any rights of indemnification the holder of the proxy may have as a director, officer or otherwise under the Company’s Corporate Charter, by laws or any
agreement, any vote of stockholders or directors, insurance policy or otherwise. 
 21. ADDITIONAL
RESTRICTIONS ON TRANSFERS OF SHARES. 
 Until such
time as the Shares are registered for trade to the public, a Participant shall not be permitted to transfer, sell, assign, pledge, hypothecate, or otherwise encumber or dispose of in any way to one or more third parties pursuant to an understanding
with such third parties any Shares, unless specifically authorized by the Board of Directors and in accordance with such terms and conditions as the Board of Directors may in its sole and absolute discretion require (including, but not limited to,
the imposition of a right of first refusal in favor of the Company and/or some or all of the then-holders of shares of the Company’s preferred stock). 
 22. MISCELLANEOUS. 
 Whenever applicable in the Plan, the
singular and the plural, and the masculine, feminine and neuter shall be freely interchangeable, as the context requires. The Section headings or titles shall not in any way control the construction of the language herein, such headings or titles
having been inserted solely for the purpose of simplified reference. Words such as “herein”, “hereof”, “hereto”, “hereinafter”, “hereby”, and “hereinabove” when used in the Plan refer to
the Plan as a whole, including any applicable Appendices, unless otherwise required by context. 

*                *      
          * 

  
 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]